Improving Care And Treatment For TB/HIV Co Infected Children Through The Establishment Of Comprehensive Pediatric TB/HIV Activities In The United Republic Of Tanzania Under The President s Emergency Plan For AIDS Relief (PEPFAR) | Apply Online

Frequently Asked Questions (FAQs)

1) What is this funding opportunity about?

This U.S. Centers for Disease Control and Prevention (CDC) funding opportunity, issued under the President's Emergency Plan for AIDS Relief (PEPFAR), supports work in the United Republic of Tanzania focused on children who are co-infected with tuberculosis (TB) and HIV. The purpose is to reduce illness and deaths tied to pediatric TB/HIV co-infection by establishing and strengthening comprehensive pediatric TB/HIV activities.

2) What is the main goal of the program?

The central aim is to reduce morbidity and mortality associated with pediatric TB/HIV co-infection. Practically, that means improving and connecting services so children can be identified earlier, diagnosed more accurately, started on effective treatment sooner, and retained in care long enough to achieve better outcomes.

3) Where will the work take place?

The work is focused on the United Republic of Tanzania.

4) Which populations are intended to benefit?

The primary intended beneficiaries are children who are co-infected with TB and HIV.

5) What kinds of activities does "comprehensive pediatric TB/HIV" imply?

Based on the description provided, comprehensive pediatric TB/HIV activities generally involve more complete and better-connected services, such as integrated screening and diagnosis, coordinated TB and HIV treatment, stronger clinical follow-up, and program systems that support consistent, high-quality care for children affected by both diseases.

6) What funding mechanism is used for this award?

The award mechanism is a cooperative agreement.

7) What does a cooperative agreement typically mean in practice?

A cooperative agreement typically indicates CDC expects substantial involvement in the project beyond simply providing funds. This often includes close collaboration with CDC technical staff, alignment with national and PEPFAR strategies, and routine performance monitoring and reporting.

8) Which federal program is this opportunity associated with?

The opportunity is associated with CFDA 93.067 (Global AIDS), indicating it sits within broader HIV program goals while specifically addressing pediatric TB/HIV overlap.

9) What is the funding activity area?

The funding activity area is health.

10) How many awards were anticipated?

The announcement anticipated up to two awards.

11) What was the estimated total funding amount available?

The estimated total funding amount was $25,000,000.

12) Is cost sharing or matching required?

No cost sharing or matching funds were required.

13) What were the award floor and ceiling amounts?

The notice lists an award ceiling and floor as 0. This commonly suggests the specific per-award amount was not stated in the summary and would be clarified in the full announcement or determined through final budgets and programmatic negotiations.

14) Who was eligible to apply?

Eligibility was broad and included U.S. and non-U.S. entities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including small businesses and small, minority-, and women-owned businesses); universities, colleges, research institutions, and hospitals; community-based and faith-based organizations; and government entities at state and local levels, including tribal governments.

15) Are both U.S. and non-U.S. organizations eligible?

Yes. The eligibility language included both U.S. and non-U.S. entities.

16) Are for-profit organizations allowed to apply?

Yes. For-profit organizations were included as eligible applicants, including small businesses and small, minority-, and women-owned businesses.

17) Can nonprofits without 501(c)(3) status apply?

Yes. The eligibility list included nonprofit organizations with or without 501(c)(3) status.

18) Are academic and healthcare institutions eligible?

Yes. Universities, colleges, research institutions, and hospitals were listed as eligible.

19) Are community-based and faith-based organizations eligible?

Yes. Community-based and faith-based organizations were included in the eligibility description.

20) Are government entities eligible?

Yes. Government entities at state and local levels, including tribal governments, were identified as eligible applicants.

21) What is a "bona fide agent" and how does it affect eligibility?

The eligibility language included "bona fide agents" of state or local governments. This would require documentation (a letter) confirming the applicant is authorized to apply on the government entity's behalf.

22) Why does the eligibility appear so broad?

The broad eligibility suggests CDC was seeking the strongest implementing partner(s) with the technical capacity and operational presence needed to run pediatric TB/HIV services at scale in Tanzania, regardless of whether the partner is governmental, academic, nonprofit, or private sector.

23) When was the opportunity posted?

The opportunity was posted on February 10, 2011 (created February 9, 2011).

24) What was the application closing date?

The original and current closing date was April 12, 2011.

25) What does it mean that the opportunity is archived?

The listing was archived on May 12, 2011, indicating the active application period has ended.

26) Where should applicants look for complete requirements?

Applicants were directed to consult the full announcement for complete requirements.

27) Who should be contacted for technical access issues?

CDC provided Procurement and Grants Office contact information for technical access issues, as referenced in the announcement.

28) How does this opportunity relate to PEPFAR strategies?

Because it is a PEPFAR-associated CDC cooperative agreement, the work is expected to align with national and PEPFAR strategies and to involve routine monitoring and reporting as part of CDC's substantial involvement.

29) What outcomes is the program trying to improve?

The described approach is intended to help find co-infected children earlier, diagnose them more accurately, start effective treatment faster, and retain them in care, all of which supports improved pediatric health outcomes and reduced deaths linked to TB/HIV co-infection.

30) Is this opportunity framed as part of HIV programming or TB programming?

It is situated within broader HIV program goals (CFDA 93.067 Global AIDS) while explicitly targeting the TB/HIV overlap in children.